RBM17 and lung carcinoma: When MSI2 is knocked down or inhibited in lung cancer cells, there is not enough MSI2 to enter the nucleus after DNA damage, so it cannot interact with RBM17 and ATR to activate ATR, which will not successfully complete DNA damage repair and increase tumor cell death.